Provide a detailed, year‑by‑year medical timeline for a patient with an 11‑year history of chronic recurrent multifocal osteomyelitis, including demographics (age, sex, ethnicity, height, weight), family history of autoimmune disease, pain locations, imaging findings, laboratory results, treatments and responses, for a CRMO specialist referral.

Medical Timeline Template for CRMO Specialist Referral

Essential Demographic and Baseline Information

Document the following patient characteristics at presentation:

• Current age, sex, and ethnicity – CRMO predominantly affects females and typically presents in childhood, though adult-onset cases are recognized 1, 2
• Height and weight at initial presentation and current – to assess growth impact over the 11-year course 3
• Family history of autoimmune conditions – specifically psoriasis, inflammatory bowel disease, inflammatory arthritis, and other autoinflammatory disorders 1, 2
• Age at symptom onset – critical for distinguishing pediatric CRMO from adult CNO patterns 1, 4

Year-by-Year Clinical Timeline Structure

For Each Year of the 11-Year History, Document:

Pain Characteristics and Locations

• Specific anatomical sites of bone pain – the anterior chest wall (clavicles, upper ribs, sternum) is involved in 78-96% of cases, followed by spine, appendicular skeleton, jaw, and pelvis 1
• Pattern of involvement – multifocal versus unifocal, as most patients exhibit multifocal disease though single-bone cases occur 1, 2
• Pain quality – specifically note pain during activity combined with increased stiffness after rest, which signals active inflammation 3
• Functional impact – range of motion limitations, gait disturbances, school/work absences 3, 4

Imaging Findings by Modality

• Plain radiographs – document sclerotic lesions, hyperostosis, or initially normal findings that later evolved 2, 5
• MRI findings – detail bone marrow edema, periosteal reaction, soft tissue changes, and number of lesions detected 2, 4
• Whole-body MRI results – essential for detecting clinically silent lesions present in up to 67% of patients 1, 3
• Bone scintigraphy – if performed, note areas of increased uptake, though interpret cautiously as an adjunct only 2, 6
• Vertebral morphometry – if spine involved, document vertebral collapse, kyphosis, or scoliosis progression 7, 8

Laboratory Results

• Inflammatory markers – ESR and CRP levels (often elevated but nonspecific) 2, 5
• Complete blood count – leucocyte counts are typically normal in CRMO 8
• Rheumatoid factor and anti-CCP – document negative results to exclude rheumatoid arthritis 8
• HLA-B27 status – if tested, as positive results may suggest overlap with axial spondyloarthritis 1, 8
• Bone biopsy results – if performed, note chronic inflammation, marrow fibrosis, plasma cell infiltrate, and negative cultures 4, 6, 8

Associated Extraosseous Manifestations

• Dermatologic findings – palmoplantar pustulosis (37-68% of adult cases), psoriasis (4-14%), severe acne (4-13%), or hidradenitis suppurativa 1, 2, 4
• Joint involvement – non-erosive peripheral arthritis (11-39%), dactylitis, or enthesitis 1
• Other features – uveitis, inflammatory bowel disease, tonsillitis, periodontitis, or necrotizing lymphadenitis 1, 8
• Timing of manifestation appearance – whether present at onset or developed during disease course 4, 8

Treatment Interventions and Responses

First-Line Therapy:

• NSAID or COX-2 inhibitor type, dose, and duration – all patients should receive maximum-tolerated NSAIDs as primary treatment 3, 2, 5
• Response assessment at 2-4 weeks – document pain reduction, functional improvement, and decreased stiffness 3
• Remission rate with NSAIDs alone – approximately 47% achieve remission with first-line therapy only 2

Adjunctive Measures:

• Physiotherapy initiation and response – specifically targeting rest-induced stiffness 3
• Short-course oral prednisolone – if used as bridging therapy while NSAIDs take effect 3

Second-Line Escalation (if inadequate response at 2-4 weeks):

• NSAID rotation attempts – document alternative NSAIDs tried before escalation 3
• Intravenous bisphosphonates (pamidronate preferred) – dose, frequency, duration, and symptomatic improvement within 6 months 3, 7
• Vertebral modeling response – if spine involved, document radiological improvement in vertebral fractures and kyphosis 7
• TNF-α inhibitors (infliximab) – as alternative second-line agent, with response timeline 3, 4

Disease-Modifying Therapy:

• Methotrexate – if added for severe bone pain or inadequate response to biologics 4, 8
• Current remission status – 84% of patients achieve remission (36% medication-free, 48% on medication) 2

Critical Diagnostic Considerations to Highlight

Emphasize the following in your referral:

• Duration from symptom onset to diagnosis – CRMO diagnosis is often delayed over one year on average due to its rarity and exclusionary nature 6, 8
• Exclusion of infectious osteomyelitis – document negative bone cultures and lack of response to antibiotics 4, 5
• Exclusion of malignancy – particularly osteosarcoma and Langerhans cell histiocytosis, via biopsy if performed 4, 8
• Genetic testing results – if monogenic autoinflammatory bone disorders were investigated, as 5 of 39 patients in one cohort had monogenic ABDs 2, 8

Common Pitfalls to Avoid in Timeline Documentation

Do not delay escalation to second-line agents if NSAIDs fail within 2-4 weeks – persistent activity-related pain with post-rest stiffness indicates ongoing inflammation requiring aggressive management to prevent long-term skeletal damage 3

Do not overlook silent lesions – up to 67% of patients have clinically silent bone involvement detectable only by whole-body MRI, which supports the need for comprehensive imaging surveillance 1, 3

Do not dismiss extraosseous manifestations – special attention to skin, joint, and systemic features is essential to avoid overlooking monogenic autoinflammatory disorders that may require different management 2, 8

Do not interpret bone scintigraphy in isolation – results must be integrated with clinical findings and other imaging modalities 2

Rationale for Specialist Referral

All adult patients with CNO should be considered for referral to an expert center, and difficult-to-treat patients must be referred if not done initially 1. Given the 11-year disease duration, multifocal involvement pattern, and complexity of long-term management including prevention of structural bone damage, this patient warrants evaluation at a tertiary referral center or rare disease reference network 1, 3.